Article Text

Download PDFPDF
Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study
  1. A P Ciardella1,2,
  2. J Klancnik3,
  3. W Schiff3,
  4. G Barile3,
  5. K Langton3,
  6. S Chang3
  1. 1Denver Health Medical Center, Denver, CO, USA
  2. 2University of Colorado Health Sciences Center, Denver, CO, USA
  3. 3Columbia University, New York, NY, USA
  1. Correspondence to: A P Ciardella MD Director of Ophthalmology, Denver Health Medical Center, 777 Bannock Street, Mail Code 0156, Denver, CO 80204, USA; Antonio.ciardelladhha.org

Abstract

Aim: To investigate the use of intravitreal triamcinolone acetonide (IVTA) for the treatment of diabetic macular oedema (DMO) unresponsive to previous laser photocoagulation.

Method: A retrospective, interventional, non-comparative case series. There were 30 eyes of 22 consecutive patients with refractory DMO. An intravitreal injection of triamcinolone acetonide at the dose of 4 mg in 0.1 ml was administered. Best corrected visual acuity was measured at each examination. In addition the central macular thickness was quantitatively measured by optical coherence tomography (OCT) examination at each visit. The amount of hard exudates deposition in the macula was subjectively evaluated using colour fundus photographs.

Results: 30 eyes of 22 patients completed 6 months or more of follow up and were included in the study. Mean (SD) visual acuity improved from 0.17 (0.12) at baseline to 0.34 (0.18), 0.36 (0.16), and 0.31 (0.17) at the 1, 3, and 6 month follow up respectively. Mean (SD) OCT macular thickness decreased from 476 (98.32) μm at baseline to 277.46 (96.77) μm, 255.33 (95.73) μm, and 331.25 (146.76) μm at the 1, 3, and 6 month follow up period respectively. 18 and seven eyes completed 12 months and 18 months of follow up, respectively. Mean (SD) visual acuity was 0.36 (0.15) and 0.35 (0.16) at the 12 and 18 month follow up period respectively. 12 eyes received two, seven eyes received three, and two eyes received four IVTA injections. The mean (SD) interval between the first and second IVTA injection was 5.7 (2.67) months and between the second and third was 5.7 (3.25) months. Hard exudates were present in the macula at baseline in all eyes. Progressive reduction in the number and size of the hard exudates was noted after IVTA in all cases. Intraocular pressure was raised above 21 mm Hg in 12 (40%) of 30 eyes. Two eyes developed posterior subcapsular cataract and two developed vitreous haemorrhage.

Conclusions: IVTA is a promising treatment for patients with DMO refractory to laser treatment. IVTA is effective in improving vision, reducing macular thickness, and inducing reabsorption of hard exudates. Further investigation is warranted to assess the safety of IVTA for the treatment of DMO.

  • CSMO, clinically significant macular oedema
  • CMO, cystoid macular oedema
  • DMO, diabetic macular oedema
  • ETDRS, Early Treatment Diabetic Retinopathy Study
  • IVTA, intravitreal triamcinolone acetonide
  • OCT, optical coherence tomography
  • PPV, pars plana vitrectomy
  • PRP, panretinal photocoagulation
  • VEGF, vascular endothelial growth factor
  • VH, vitreous haemorrhage
  • triamcinolone
  • diabetic macular oedema
  • optical coherence tomography
  • CSMO, clinically significant macular oedema
  • CMO, cystoid macular oedema
  • DMO, diabetic macular oedema
  • ETDRS, Early Treatment Diabetic Retinopathy Study
  • IVTA, intravitreal triamcinolone acetonide
  • OCT, optical coherence tomography
  • PPV, pars plana vitrectomy
  • PRP, panretinal photocoagulation
  • VEGF, vascular endothelial growth factor
  • VH, vitreous haemorrhage
  • triamcinolone
  • diabetic macular oedema
  • optical coherence tomography

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • None of the authors has any financial interest in the subject matter of the presentation.

  • Meeting presentation: AAO Annual Meeting November 2003.